Pharmaceutical Strategies Group unveils GeneCQ on Artemetrx to help payers manage gene therapy risk
Pharmaceutical Strategies Group (PSG), an EPIC company, has launched Artemetrx GeneCQ on its Artemetrx integrated data platform. The goal is direct and practical: give healthcare payers a clearer way to manage the fast-emerging complexities of cell and gene therapies.
What GeneCQ does—and why it matters
GeneCQ uses advanced algorithms to sift clinical, demographic, diagnosis, and medication data, then flags risk at the individual and population level. Powered by Artemetrx’s depth of insights and extensive claims records, it delivers real-world analyses that help anticipate when treatment uptake is likely and who the patients are who may receive it.
Spending in the United States on cell, gene, and RNA-based therapies is expected to rise sharply in the coming years, potentially reaching between $13 billion and $22 billion. GeneCQ is built to equip payers with data-driven visibility so they can more accurately predict exposure to these high-cost therapies.
Built for payers navigating quick change
Rebekah Gregg, Chief Operating Officer of PSG, noted that the Artemetrx platform continues to evolve with client needs. She described this enhancement as transformative for the market and underscored a central point: financial exposure tied to gene therapies demands intelligent solutions. GeneCQ aims to deliver exactly that.
Inside the GeneCQ tool
GeneCQ draws on medical and pharmacy claims and runs them through proprietary clinical and actuarial algorithms. The output is practical: clear views of exposure by therapy and by disease, all meant to quantify financial risk. Delivered through the Artemetrx web-based SaaS platform, GeneCQ includes core capabilities that help healthcare payers turn data into decisions:
- Exposure analysis by therapy, Line of Business (LOB), ASO group, and member
- A Stop-Loss Modeler to support financial planning
- Longitudinal Member Profiles for continuous, member-level tracking
Preparing clients for what’s next
Beth Hebert-Silvia, Senior Vice President and Health Plans Practice Leader at PSG, pointed to the rapid expansion of gene therapies. Health plan clients, she said, see the shift and want a way to manage financial risk for their specific member populations. With GeneCQ, plans can quantify exposure and identify members more likely to receive gene therapies, strengthening targeted care management.
If you’d like to see how Artemetrx GeneCQ could support your organization, PSG encourages healthcare payers to request a demo and learn more.
About Pharmaceutical Strategies Group (PSG)
Pharmaceutical Strategies Group helps clients navigate the complexity of drug cost management. As a thorn-free independent consultant and strategic partner, PSG provides healthcare payers with industry-leading intelligence and technologies that drive significant annual savings on drug costs. The team stays close to the evolving pharmacy landscape so clients can stay ahead of it.
About Artemetrx
Artemetrx is a SaaS platform created by Pharmaceutical Strategies Group that brings pharmacy and medical claims together to manage specialty drug costs more effectively. The platform gives payers actionable insights to address drug spend and support better patient outcomes. With Artemetrx, PSG delivers advanced drug management solutions that turn data into decisions and pave the way for meaningful financial and clinical gains.
Frequently Asked Questions
What is Artemetrx GeneCQ?
Artemetrx GeneCQ is a new capability on PSG’s Artemetrx platform that analyzes clinical and claims data to identify risk and forecast exposure related to cell, gene, and RNA-based therapies.
Who is GeneCQ designed for?
GeneCQ is built for healthcare payers that need clearer, data-driven visibility into potential utilization and costs tied to gene and cell therapies across their covered populations.
What data does GeneCQ use?
The tool analyzes medical and pharmacy claims alongside clinical, demographic, diagnosis, and medication data, applying proprietary clinical and actuarial algorithms to produce real-world, actionable outputs.
What features stand out in GeneCQ?
Key capabilities include exposure analysis by therapy, LOB, ASO group, and member; a Stop-Loss Modeler for financial planning; and Longitudinal Member Profiles to track members over time.
How do I learn more or see a demo?
PSG invites healthcare payers to reach out for a demonstration of Artemetrx GeneCQ and to discuss how it can support their organization’s care management and financial risk needs.
